GW 610 is an antitumor benzothiazole that shows growth-inhibitory activity against several cancer cell lines. In MCF-7 and MDA 468 human cancer cell lines, potent antiproliferative activity (growth inhibition (GI50) < 0.1 nM) was observed. Potent and selective activity was also observed in the NCI 60 human cancer cell line panel. In contrast with previously reported 2-(4-aminophenyl)benzothiazoles, GW 610 is not reliant on induction of cytochrome P 1A1 (CYP1A1) expression for antitumor activity.
GW 610 is a fluorinated 2-arylbenzothiazole and potential antitumor drug, which shows potent and selective inhibitory activity against breast, lung, and colon cancer cell lines. Studies suggest that the species-specific partial agonism of the aryl hydrocarbon receptor shown by GW 610 plays an important role in its anti-proliferative activity.
